safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
Published 4 years ago • 1.3K plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
1:57
aramis: efficacy and safety of darolutamide in nmcrpc
-
12:42
pca commentary - nmcrpc and androgen receptor inhibition: enzalutamide, apalutamide and darolutamide
-
3:40
this is spartan! apalutamide treatment for nmcrpc
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc
-
6:12
video 23 - cancer recurrence - my prostate cancer story
-
31:13
titan trial | investigating the addition of apalutamide to androgen deprivation therapy
-
19:54
casodex, spaceoar, and biopsy reports | ask a prostate expert
-
0:42
enzalutamide in the non-metastatic setting for crpc
-
5:20
apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer.
-
2:02
assessing the role of darolutamide in crpc
-
2:07
impact of prior therapy on enzalutamide in nmcrpc: post-hoc analysis of prosper
-
2:46
aramis: darolutamide in patients with nmcrpc
-
1:20
panther: apalutamide abiraterone in black and white mcrpc patients
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
3:06
titan trial
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment
-
1:03
kim n. chi, md, outlines the safety profile of apalutamide
-
1:06
dr. bradley on adverse events associated with enzalutamide and apalutamide in prostate cancer
-
2:11
straightforward study design: spartan trial of apalutamide for nmcrpc
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
4:36
nonmetastatic crpc: considerations for apalutamide